IL111402A - Suspension of loteprednol etabonate for ear eye or nose treatment - Google Patents

Suspension of loteprednol etabonate for ear eye or nose treatment

Info

Publication number
IL111402A
IL111402A IL11140294A IL11140294A IL111402A IL 111402 A IL111402 A IL 111402A IL 11140294 A IL11140294 A IL 11140294A IL 11140294 A IL11140294 A IL 11140294A IL 111402 A IL111402 A IL 111402A
Authority
IL
Israel
Prior art keywords
suspension
loteprednol etabonate
nose treatment
ear eye
ear
Prior art date
Application number
IL11140294A
Other languages
English (en)
Other versions
IL111402A0 (en
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Corp filed Critical Pharmos Corp
Publication of IL111402A0 publication Critical patent/IL111402A0/xx
Publication of IL111402A publication Critical patent/IL111402A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Resins (AREA)
  • Steroid Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Adhesives Or Adhesive Processes (AREA)
IL11140294A 1993-10-25 1994-10-25 Suspension of loteprednol etabonate for ear eye or nose treatment IL111402A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/142,743 US5540930A (en) 1993-10-25 1993-10-25 Suspension of loteprednol etabonate for ear, eye, or nose treatment

Publications (2)

Publication Number Publication Date
IL111402A0 IL111402A0 (en) 1994-12-29
IL111402A true IL111402A (en) 2000-12-06

Family

ID=22501105

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11140294A IL111402A (en) 1993-10-25 1994-10-25 Suspension of loteprednol etabonate for ear eye or nose treatment

Country Status (17)

Country Link
US (2) US5540930A (fr)
EP (1) EP0730443B1 (fr)
JP (1) JP3570720B2 (fr)
KR (1) KR100341497B1 (fr)
AT (1) ATE217523T1 (fr)
AU (1) AU697617B2 (fr)
BR (1) BR9407958A (fr)
CA (1) CA2174550C (fr)
DE (1) DE69430635T2 (fr)
DK (1) DK0730443T3 (fr)
ES (1) ES2179851T3 (fr)
HU (1) HU227316B1 (fr)
IL (1) IL111402A (fr)
NZ (1) NZ275749A (fr)
PT (1) PT730443E (fr)
SG (1) SG48768A1 (fr)
WO (1) WO1995011669A1 (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (ko) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
WO1999037286A1 (fr) * 1998-01-22 1999-07-29 Santen Pharmaceutical Co., Ltd. Collyre a suspension de fluorometholone
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
WO2000012137A1 (fr) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Compositions contenant de la cyclodextrine et un agent conservateur
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
WO2000078297A2 (fr) * 1999-06-22 2000-12-28 Boehringer Ingelheim International Gmbh Solution de xylometazoline et d'oxymetazoline stable
FR2796553B1 (fr) * 1999-07-22 2001-09-28 Warner Lambert Co Suspension de tixocortol pivalate, collutoire a base de celle-ci et conditionnement la contenant
ES2207549T3 (es) 1999-09-24 2004-06-01 Alcon Inc. Formulaciones en suspension topicas que contienen ciprofloxacino y desametasona.
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
EP1142565A4 (fr) * 1999-10-20 2004-03-17 Teijin Ltd Compositions therapeutiques aqueuses
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
MXPA02005007A (es) * 1999-11-18 2004-08-12 Alcon Inc Uso de un antagonista h1 y un esteroide inocuo para tratar condiciones oculares.
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US20030165568A1 (en) * 2000-05-15 2003-09-04 Giuseppe Colombo Stabilized steroidal suspension
WO2002007704A2 (fr) 2000-07-26 2002-01-31 Alcon Universal Ltd. Procede ameliore de fabrication de compositions contenant de la ciprofloxacine et de l'hydrocortisone
ATE424808T1 (de) * 2000-11-15 2009-03-15 Chandavarkar Mohan A Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
EP1341541A4 (fr) * 2000-11-16 2004-11-17 Alcon Mfg Ltd Therapie combinee abaissant et regulant la tension intraoculaire
US20030139382A1 (en) * 2001-09-21 2003-07-24 Alcon, Inc. Method of treating middle ear infections
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
US7727549B2 (en) * 2002-07-15 2010-06-01 Alcon, Inc. Pharmaceutical compositions for otic use
WO2004035005A2 (fr) * 2002-10-18 2004-04-29 Echols Joel S Formulation lacrymale a trois couches
JP2006513217A (ja) * 2002-12-20 2006-04-20 コントロール・デリバリー・システムズ・インコーポレイテッド 眼内用途のためのステロイド組成物
DE122011100019I1 (de) 2003-01-21 2011-11-03 Senju Pharma Co Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure.
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050197303A1 (en) * 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
AU2004285592B2 (en) * 2003-11-03 2010-02-18 Norton Healthcare, Ltd. Soft steroid compositions for use in dry powder inhalers
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
JP4820648B2 (ja) * 2003-12-02 2011-11-24 千寿製薬株式会社 ロテプレドノールエタボネート水性懸濁液剤
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
WO2005072701A1 (fr) 2004-01-20 2005-08-11 Allergan, Inc. Compositions pour therapie localisee de l'oeil, de preference a base de triamcinolone acetonide et d'acide hyaluronique
US8957034B2 (en) * 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
BRPI0509220A (pt) * 2004-03-25 2007-09-04 Bausch & Lomb método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
US8653055B2 (en) * 2004-09-15 2014-02-18 Teva Animal Health, Inc. Corticosteroid having low systemic absorption
WO2006043965A1 (fr) * 2004-10-14 2006-04-27 Allergan, Inc. Compositions ophtalmiques therapeutiques contenant des excipients sans danger pour la retine et leurs methodes
AU2006244245B2 (en) * 2005-05-10 2010-11-18 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
US20060257487A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
EP1928439A4 (fr) * 2005-09-26 2009-04-29 Piedmont Pharmaceuticals Llc Procedes de traitement et de prevention de l'otite moyenne par le biais d'agents qui ameliorent la penetration chimique pour faciliter la delivrance de medicament transmembranaire dans l'oreille moyenne
WO2007037886A2 (fr) * 2005-09-26 2007-04-05 Piedmont Pharmaceuticals Llc Procedes de traitement et de prevention de l'otite moyenne par le biais de tensioactifs non ioniques pour faciliter la delivrance de medicament transmembranaire dans l'oreille moyenne
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CA2602577C (fr) 2005-10-18 2015-03-31 Allergan, Inc. Therapie oculaire utilisant des derives de glucocorticoides traversant selectivement les tissus du segment posterieur
US20070093461A1 (en) * 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
US20070110812A1 (en) * 2005-11-14 2007-05-17 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US7955632B2 (en) * 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US20070128251A1 (en) * 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
EP2004203A4 (fr) 2006-03-28 2010-03-31 Javelin Pharmaceuticals Inc Formulations de diclofénac et de cyclodextrine bêta à faible dosage
ZA200808114B (en) * 2006-03-28 2009-12-30 Javelin Pharmaceuticals Inc Formulations of low dose non-steroidal anti-inflammatory drugs and betacyclodextrin
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
WO2008002118A1 (fr) * 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Formulation ophtalmique en suspension d'étabonate de loteprednol et de chlorhydrate de ciprofloxacine
KR101230804B1 (ko) 2006-07-21 2013-02-08 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 향상된 흡수를 갖는 경점막 전달 장치
WO2008027341A2 (fr) * 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
WO2008027340A2 (fr) * 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
US20100215580A1 (en) * 2006-09-08 2010-08-26 The Johns Hopkins University Compositions and methods for enhancing transport through mucus
TWI415629B (zh) 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
US20080119448A1 (en) * 2006-11-02 2008-05-22 Friedlaender Mitchell H Methods of treating an ocular allergy with low dose dexamethasone
WO2008057364A1 (fr) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Procédé destiné à traiter une blépharite
CN101721714B (zh) * 2009-12-18 2011-12-07 重庆莱美药业股份有限公司 实体瘤被动靶向性抗癌前药及其制备方法
WO2011106702A2 (fr) 2010-02-25 2011-09-01 The Johns Hopkins University Délivrance prolongée d'agents thérapeutiques à un compartiment oculaire
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
BR112013026534A2 (pt) * 2011-04-22 2016-12-27 Alcon Res Ltd composição oftálmica com um sistema de realce da viscosidade tendo dois diferentes agentes de realce da viscosidade
KR101944367B1 (ko) 2011-08-18 2019-01-31 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 부프레노르핀 운반용 약물남용 억제 점막 부착 장치
WO2013043387A1 (fr) 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Compositions ophtalmiques en gel
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
EP2825206A1 (fr) 2012-03-16 2015-01-21 The Johns Hopkins University Formulations à libération contrôlée pour l'administration d'inhibiteurs du hif-1
CA2867203C (fr) 2012-03-16 2016-09-20 The Johns Hopkins University Conjugues copolymere multi-blocs non lineaire-medicament pour l'administration de principes actifs
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360040B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
AU2013256092B2 (en) * 2012-05-03 2017-11-23 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256130B2 (en) 2012-05-03 2017-12-21 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9889208B2 (en) 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
CN103565740A (zh) * 2012-07-25 2014-02-12 天津金耀集团有限公司 依碳氯替泼诺混悬滴眼液
CN103565742A (zh) * 2012-07-25 2014-02-12 天津金耀集团有限公司 氟米龙滴眼液
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CA2900652C (fr) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Composes therapeutiques et utilisations de ceux-ci
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
CN107073008A (zh) * 2014-11-07 2017-08-18 参天制药株式会社 眼科用水性组合物
CA2974715C (fr) 2015-01-27 2020-05-05 The Johns Hopkins University Formulations d'hydrogel hypotoniques pour le transport ameliore d'agents actifs au niveau de surfaces muqueuses
CN106279325A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CN106279324A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106892952A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CN106892953A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
WO2018048746A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
US12023344B2 (en) 2022-05-25 2024-07-02 Famygen Life Sciences, Inc. Topical otic, ophthalmic, and nasal corticosteroid formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS6041607A (ja) * 1983-08-12 1985-03-05 Otsuka Pharmaceut Co Ltd 軟膏基剤
JPS6143114A (ja) * 1984-08-03 1986-03-01 Takeda Chem Ind Ltd 虹彩・毛様体疾患治療用眼局所投与剤
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5149693A (en) * 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and fluorometholone for topical ophthalmic use
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
CA2003198C (fr) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Solutions ophtalmiques aqueuses et methode de conservation
US5277901A (en) * 1990-01-05 1994-01-11 Allergan, Inc. Ophthalmic compositions and methods for preserving and using same

Also Published As

Publication number Publication date
PT730443E (pt) 2002-11-29
HU227316B1 (en) 2011-03-28
JPH09504294A (ja) 1997-04-28
ES2179851T3 (es) 2003-02-01
HUT74882A (en) 1997-02-28
CA2174550A1 (fr) 1995-05-04
AU697617B2 (en) 1998-10-15
DE69430635D1 (de) 2002-06-20
KR960705541A (ko) 1996-11-08
SG48768A1 (en) 1998-05-18
DE69430635T2 (de) 2003-01-02
JP3570720B2 (ja) 2004-09-29
NZ275749A (en) 1998-02-26
HU9601081D0 (en) 1996-06-28
BR9407958A (pt) 1996-11-26
ATE217523T1 (de) 2002-06-15
CA2174550C (fr) 2002-10-01
DK0730443T3 (da) 2002-09-09
AU7983594A (en) 1995-05-22
EP0730443A4 (fr) 1997-11-05
KR100341497B1 (ko) 2002-12-05
IL111402A0 (en) 1994-12-29
EP0730443B1 (fr) 2002-05-15
EP0730443A1 (fr) 1996-09-11
US5540930A (en) 1996-07-30
US5747061A (en) 1998-05-05
WO1995011669A1 (fr) 1995-05-04

Similar Documents

Publication Publication Date Title
IL111402A0 (en) Suspension of loteprednol etabonate for ear, eye or nose treatment
EP0777451A4 (fr) Systeme de liberation ophtalmique
AU7729998A (en) Active principles and gas containing microparticles
IL106128A0 (en) Vitamin d derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
CA2342211A1 (fr) Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
CA2310222A1 (fr) Nouvelle composition de matiere
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
WO2000018388A3 (fr) Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
ES488888A1 (es) Procedimiento de fabricacion de una suspension acuosa de alumina
MXPA02004617A (es) Lipoxin a4 y sus analagos para el tratamiento de ojo reseco.
MY106661A (en) Therapeutic agent
WO2000018387A3 (fr) Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
IL113178A (en) 8alpha-3-hydroxyestra-1,3,5(11)tetraen-17-one( 9(11)-dehydro-8-isoestrone) its preparation and pharmaceutical composition containing it
IL87623A (en) Compositions containing biosynthetic pesticide products and 1,2-benzisothiazolin-3-one as stabilizer, their production and their use
IT1254627B (it) Formulazioni di steroidi
AU641411B2 (en) Nitrofurantoin crystals
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
AU6295094A (en) Compositions for the treatment of eye diseases

Legal Events

Date Code Title Description
FF Patent granted
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
FF Patent granted
KB Patent renewed
EXP Patent expired